Haber D A, Park S, Maheswaran S, Englert C, Re G G, Hazen-Martin D J, Sens D A, Garvin A J
Laboratory of Molecular Genetics, Massachusetts General Hospital Cancer Center, Boston 02129.
Science. 1993 Dec 24;262(5142):2057-9. doi: 10.1126/science.8266105.
A human Wilms tumor cell line (RM1) was developed to test the tumor suppressor activity of WT1, a zinc finger transcription factor that is expressed in the developing human kidney and is mutationally inactivated in a subset of Wilms tumors. Transfection of each of four wild-type WT1 isoforms suppressed the growth of RM1 cells. The endogenous WT1 transcript in these cells was devoid of exon 2 sequences, a splicing alteration that was also detected in varying amounts in all Wilms tumors tested but not in normal kidney. Production of this abnormal transcript, which encodes a functionally altered protein, may represent a distinct mechanism for inactivating WT1 in Wilms tumors.
一种人类肾母细胞瘤细胞系(RM1)被建立起来,用于测试WT1的肿瘤抑制活性。WT1是一种锌指转录因子,在发育中的人类肾脏中表达,并且在一部分肾母细胞瘤中发生突变失活。四种野生型WT1异构体中的每一种转染都抑制了RM1细胞的生长。这些细胞中的内源性WT1转录本缺乏外显子2序列,这种剪接改变在所有测试的肾母细胞瘤中也有不同程度的检测到,但在正常肾脏中未检测到。这种编码功能改变蛋白质的异常转录本的产生,可能代表了肾母细胞瘤中WT1失活的一种独特机制。